Generated Narrative: DocumentReference asm-alicia-example-2

RelatedMedicalIssue: Human immunodeficiency virus infection

identifier: http://example.org/3

version: 1.0

status: Current

docStatus: Final

category: Adverse Effects Management

subject: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#EU/1/18/1289/001,https://www.who-umc.org/phpid#0xF79CABF272B6A7EEF104DDDA44E827gy; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription

author: hypertuny

description:

Biktarvy, consisting of bictegravir, emtricitabine and tenofovir alafenamide, is a significant medication in the treatment of HIV and AIDS. This fixed-dose combination antiretroviral drug, approved for use in the United States in February 2018 and in the European Union in June 2018, is a combination therapy, often termed as highly active antiretroviral therapy. This therapy involves using two or more types of antiretroviral drugs. Each tablet of Biktarvy contains 50 milligrams bictegravir, 200 milligrams emtricitabine, and 25 milligrams tenofovir alafenamide, and is taken orally once daily.

content

Attachments

-ExtensionContentTypeLanguageUrlTitleDuration
*text/htmlEnglishhttps://www.youtube.com/watch?v=HpndrPLs1Y8Biktarvy - Video explaining the medication and how it works.715
 <duration value="715"/> </attachment> </content> </DocumentReference>